- UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapy
- Highly experienced team ready to support ATMP innovators at all stages
- Offering comprehensive range of services from early process and analytical development through cGMP manufacturing for clinical trials
Stevenage, UK and Laupheim, Germany, September 13, 2023– Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that it has received the cGMP Manufacturing Compliance Certificate, following the successful inspection by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) at its UK site. The ATMP business was announced in early 2021 and the facility is located in the Cell and Gene Therapy Catapult’s Manufacturing Innovation Centre in Stevenage.